Japanese Society of Anxiety and Related Disorders/Japanese Society of Neuropsychopharmacology: Clinical practice guideline for social anxiety disorder (2021).
Japan
anxiety disorders
practice guidelines
social anxiety disorders
treatment
Journal
Neuropsychopharmacology reports
ISSN: 2574-173X
Titre abrégé: Neuropsychopharmacol Rep
Pays: United States
ID NLM: 101719700
Informations de publication
Date de publication:
09 2023
09 2023
Historique:
revised:
05
06
2023
received:
11
05
2023
accepted:
21
06
2023
medline:
13
9
2023
pubmed:
25
8
2023
entrez:
25
8
2023
Statut:
ppublish
Résumé
The development of clinical practice guidelines for social anxiety disorder began in March 2018 when the Joint Clinical Practice Guideline Development Committee for Anxiety and Obsessive-Compulsive Disorders was formed by the Japanese Society of Anxiety and Related Disorders and Japanese Society of Neuropsychopharmacology to jointly develop guidelines for anxiety and obsessive-compulsive disorders. Based on the universal concept of evidence-based medicine, three clinical questions (CQs) about pharmacotherapy and psychotherapy were developed for clinical guidelines for social anxiety disorder, panic disorders, and obsessive-compulsive disorder in accordance with the Minds "Manual for Guidelines Development 2017 by the Japan Council for Quality Health Care: CQ1-"What is the recommended pharmacotherapy for social anxiety disorder in adults?"; CQ2-"What is the recommended psychotherapy (psychological intervention) for social anxiety disorder in adults?"; and CQ3-"What are the recommendations regarding monotherapy and combination therapy for social anxiety disorder in adults in terms of pharmacotherapy and psychotherapy (psychological interventions)?" Summarized recommendations for social anxiety disorder in adults are selective serotonin reuptake inhibitors and serotonin-norepinephrine reuptake inhibitor for CQ1, cognitive behavioral therapy for CQ2, and there are no recommendations regarding monotherapy and combination therapy for CQ3. These were answered by considering the balance between benefits and harms based on systematic reviews of each. The aim of this brief guideline for the standard-of-care (i.e., medical treatment) for social anxiety disorder in adults (18 years and older) was to help "shared decision making," in which medical professionals, including physicians, and patients share scientific evidence to decide on a course of treatment.
Identifiants
pubmed: 37624975
doi: 10.1002/npr2.12365
pmc: PMC10496046
doi:
Substances chimiques
Anti-Anxiety Agents
0
Types de publication
Journal Article
Practice Guideline
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
288-309Informations de copyright
© 2023 The Authors. Neuropsychopharmacology Reports published by John Wiley & Sons Australia, Ltd on behalf of the Japanese Society of Neuropsychopharmacology.
Références
J Clin Psychiatry. 2013 Jun;74(6):595-602
pubmed: 23842011
Neuropsychopharmacol Rep. 2023 Sep;43(3):288-309
pubmed: 37624975
Psychother Psychosom. 2019;88(4):244-246
pubmed: 31121592
Dtsch Arztebl Int. 2014 Jul 7;111(27-28):473-80
pubmed: 25138725
Behav Res Ther. 2007 Apr;45(4):819-28
pubmed: 16784722
Curr Med Res Opin. 2016;32(4):749-57
pubmed: 26808688
BMC Psychiatry. 2014;14 Suppl 1:S1
pubmed: 25081580
BMC Psychiatry. 2009 Jun 15;9:37
pubmed: 19527506
Psychother Psychosom. 2009;78(6):383-4
pubmed: 19738407
Lancet Psychiatry. 2014 Oct;1(5):368-76
pubmed: 26361000
Cochrane Database Syst Rev. 2017 Oct 19;10:CD001206
pubmed: 29048739
Gen Hosp Psychiatry. 2006 Mar-Apr;28(2):178-80
pubmed: 16516070